

# **ArTec, Inc., of Reno, Nevada announces Korean Partners and its Mission**

## **Monday September 20, 7:00 am ET**

RENO, Nev.--(BUSINESS WIRE)--Sept. 20, 2004--ArTec, Inc., (Pink Sheets: [ATKJ - News](#)) announces its Korean partners includes the eminent Dr. Tai Ho Chung M.D. Ph.D., inventor of Tubercin, Mr. CC Chung (son of Dr. Tai Ho Chung) and Dr. David Chai, Ph.D. The considerable experience in medical research and pharmaceutical manufacturing will greatly enhance ArTec, Inc., accomplishing its mission. Dr. Ronald Shinn, Ph.D. is the other partner that was selected as the Chairman, President and CEO. Dr. Ronald Shinn, Ph.D. a graduate of University of California at Berkely and an American citizen by birthright has been a strong advocate for the use of Tubercin to combat Cancer in the last four years. THE MISSION of ArTec is to seek US FDA and South Korea FDA approvals as soon as funds are available. ArTec, Inc., is sublicensed by Shinn Capital Group, Inc., to manufacture and distribute Tubercin in the United States and Canada. Tubercin is a finished product with a history of over 17 years of clinical experience in South Korea with no adverse side effects.

What is Tubercin? Tubercin is "carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extract from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects". This was cited in the August 14, 2001 (Patent Number 6274356) US Patent Documents for public information. For further information, the US Patent and Trademark Office's Official web site is retrievable at our web site: [www.artec-inc.net](http://www.artec-inc.net).

Presently, Dr. Tai Ho Chung and his staff are working on a nasal spray for Tubercin. This will be an addition to the injectile administration of Tubercin. The advantages to the nasal spray are conveniences and speed of effectiveness. ArTec is pleased with the progress of the nasal spray and has samples ready for display.

At this time there have been genuine proposals to make both the nasal sprays and injectiles available for humans and animals (especially pertaining to the equine family of horses). Many Grey horses contract Melanoma Cancer and Tubercin would be a desirable product for them. In addition, Arthritis affects many horses and Tubercin could be used as a pain reliever. This does not mean that other animals do not contract cancer and suffer Arthritis. Tubercin would like to explore the animal field of medicinal products.

It would be premature to mention other products that involve Tubercin, such as, ointments of various kinds. We will keep you posted on our progress.

Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.